ATR-COSF uses a supernatant based formulation containing an active recombinant human domain of the protein, filaggrin.

Ex vivo data in two models of recent cosmetic surgery explants showed visible improvements in fine lines, wrinkles and elasticity after a single dose with the ATR-COSF cosmetic product candidate

Continued improvement seen up to 48 hours

First-in-human study with ATR-COSF initial results anticipated by year end

Further details to be presented in a live presentation at BIO-Europe®

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.